The matching half-life time of Zirconium-89 and the circulation time of monoclonal antibodies (mAbs) are most convenient for bioimaging. Our broad portfolio of bifunctional DFO star (DFO*) chelators allow conjugation with mAbs in several ways. The formed ⁸⁹Zr-immunoconjugates show superior complex stabilities which lead to a significantly decreased accumulation of free Zirconium-89 in bone compared to other chelators. The reduced Zirconium-89 bone uptake minimizes undesirable radiation to the bone marrow.
ABX advanced biochemical compounds is a global frontrunner in radiopharmaceuticals, with a focus on positron emission tomography (PET) tracers. We develop and produce all compounds and components for any kind of radiotracer – from PET and SPECT precursors, PET reagent kits and cassettes, to complete radiopharmaceutical drug production in GMP environment.
Based in Radeberg, Germany, and founded in 1997, our team of more than 350 employees is specialised in custom synthesis and manufacturing of precursors and peptides according to GMP for active pharmaceutical ingredients. Thanks to our expertise combined with bleeding edge equipment, we reach highest research, production, and quality standards.
ABX is the only service provider of radiopharmaceutical production with a complete and independent supply chain – from precursor or peptide to excipients and sterile disposables.